Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Faculty Hospital Bulovka, Prague, Czech Republic.
Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.
HIV Med. 2022 May;23(5):546-552. doi: 10.1111/hiv.13194. Epub 2021 Oct 26.
People living with HIV (PLWH) are at higher risk of poorer COVID-19 outcomes. Vaccination is a safe and effective method of prevention against many infectious diseases, including COVID-19. Here we investigate the strategies for national COVID-19 vaccination programmes across central and eastern Europe and the inclusion of PLWH in vaccination programmes.
The Euroguidelines in Central and Eastern Europe Network Group consists of experts in the field of infectious diseases from 24 countries in the region. Between 1 November 2020 and 19 March 2021 the group proceeded an on-line survey consisting of 20 questions.
Twenty-two countries (out of 24 invited) participated in the survey and 20/22 countries in the period between December 2020 and March 2021 had already started their COVID-19 vaccination programme. In total, seven different vaccines were used by participating countries. In 17/21 countries (81%), vaccinated persons were centralized within the national registry. In 8/21 countries (38%) PLWH were prioritized for vaccination (the Czech Republic, Greece, Hungary, Lithuania, Montenegro, Romania, Slovakia, Slovenia) and the Czech Republic, Greece and Serbia had put in place national guidelines for vaccination of PLWH. In 14/20 countries (70%) vaccination was only provided by designated centres. Eighteen respondents (18/21; 85.7%) reported that they planned to follow up HIV patients vaccinated against COVID-19, mainly by measuring antibody levels and checking COVID-19 incidence (11/21; 52.3%).
This survey-based study suggests that there are significant differences in terms of prioritizing PLWH, the types of vaccines used, vaccination coverage, and the development and implementation of a vaccination programmes within the region. Regardless of heterogenicity and existing barriers within the region, systematic vaccination in PLWH should have the highest priority, especially in those with severe immunodeficiency, risk factors, and in the elderly, aiming for prompt and high vaccination coverage.
感染 HIV 的人(PLWH)患 COVID-19 的风险更高。疫苗接种是预防包括 COVID-19 在内的许多传染病的安全有效方法。在这里,我们研究了中东欧国家的 COVID-19 疫苗接种计划策略以及将 PLWH 纳入疫苗接种计划。
东欧和中欧 Euroguidelines 网络集团由该地区 24 个国家的传染病专家组成。2020 年 11 月 1 日至 2021 年 3 月 19 日,该小组进行了一项包含 20 个问题的在线调查。
24 个受邀国家中有 22 个国家参与了调查,2020 年 12 月至 2021 年 3 月期间 20/22 个国家已经开始了 COVID-19 疫苗接种计划。总共有七个不同的疫苗被参与国家使用。在 21 个国家中的 17 个(81%),接种者集中在国家登记册中。在 21 个国家中的 8 个(38%),PLWH 被优先接种疫苗(捷克共和国、希腊、匈牙利、立陶宛、黑山、罗马尼亚、斯洛伐克、斯洛文尼亚),捷克共和国、希腊和塞尔维亚已经制定了 PLWH 疫苗接种国家指南。在 20 个国家中的 14 个(70%),疫苗接种仅由指定中心提供。21 名受访者中的 18 名(18/21;85.7%)报告说,他们计划跟踪接种 COVID-19 疫苗的 HIV 患者,主要通过测量抗体水平和检查 COVID-19 发病率(21/21;52.3%)。
这项基于调查的研究表明,在优先考虑 PLWH、使用的疫苗类型、疫苗接种覆盖率以及该地区疫苗接种计划的制定和实施方面,存在显著差异。尽管该地区存在异质性和现有障碍,但应优先为 PLWH 进行系统疫苗接种,特别是在那些免疫严重缺陷、有风险因素和老年人中,以实现快速和高疫苗接种覆盖率。